A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Sponsor:

Johnson and Johnson - J&J

Sponsor Study ID:

COPERNICUS (61186372NSC2012)

CTO #:

104164

NCT Number:

NCT06667076

Phase:

II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Lung

Study Objectives:

The primary objective of this study is to assess the antitumor activity of amivantamab SC and Lazertinib (Cohort 1), and amivantamab SC and chemotherapy (Cohort 2) in participants with EGFRm NSCLC.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)